Tag Archives: vaccines

Ebola Crisis Could Spur Broader R&D Efforts

Up until a few months ago, there was little industry interest or public support for developing vaccines and treatments to combat the Ebola virus. Now the rush is on to launch clinical trials of therapies with some potential effectiveness against the disease. The situation has also encouraged FDA and regulatory authorities to facilitate these efforts […]
Posted in healthcare, R&D, Regulatory | Also tagged , , | Leave a comment

NIH Begins Human Safety Study of Ebola Candidate Vaccine

Initial human testing on a vaccine to prevent Ebola virus co-developed by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and GlaxoSmithKline (GSK) has begun. The study is the first of several Phase 1 clinical trials that will examine the investigational NIAID/GSK Ebola vaccine and an experimental […]
Posted in R&D | Also tagged , , , , | Leave a comment

Positive Results for Ebola Vaccine

Immunovaccine Inc., a clinical stage vaccine company, announced on Aug. 25 positive results for a vaccine formulated in its DepoVax technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH. In a preliminary study, four vaccinated cynomolgus macaque, which are particularly sensitive to the Ebola […]
Posted in Global, healthcare | Also tagged | Leave a comment

GSK Submits Malaria Vaccine Candidate for EMA Approval

GSK announced that it has submitted a regulatory filing to the European Medicines Agency (EMA) for its malaria vaccine candidate, RTS,S. RTS,S is intended for use against the Plasmodium falciparum malaria parasite, which is most prevalent in sub-Saharan Africa (SSA). It is estimated that malaria accounts for approximately 90% of deaths in SSA, of which 77% occur […]
Posted in Europe, Global, Regulatory | Also tagged , , , | Leave a comment

Sanofi Reports Progress Toward First Dengue Vaccine

Sanofi Pasteur, the vaccines division of Sanofi, reports that results of an efficacy study is a step closer to making dengue the next vaccine-preventable disease. Sanofi points to The Lancet’s published results showing the overall efficacy of the drug maker’s vaccine against symptomatic dengue in 56.5% in children aged 2 to 14 years old after […]
Posted in Europe, R&D | Also tagged , , , | Leave a comment
  • Categories

  • Meta